Evidence map›Paper›PMID 36969911›Full record

ArticleNano today2022

Use of a Liver-targeting Nanoparticle Platform to Intervene in Peanut-induced anaphylaxis through delivery of an Ara h2 T-cell Epitope.

Qi Liu, Xiang Wang, Yu-Pei Liao, Chong Hyun Chang, Jiulong Li, Tian Xia, Andre E Nel

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano today, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Towards mRNA therapeutics 2.0.Nature reviews. Drug discovery · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Nanomaterials for antigen-specific immune tolerance therapy.Drug delivery and translational research · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Qi LiuCenter of Environmental Implications of Nanotechnology (UC CEIN), University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-1598-8253
Xiang WangCenter of Environmental Implications of Nanotechnology (UC CEIN), University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-6647-0684
Yu-Pei LiaoCenter of Environmental Implications of Nanotechnology (UC CEIN), University of California, Los Angeles, CA 90095, USA.
Chong Hyun ChangCenter of Environmental Implications of Nanotechnology (UC CEIN), University of California, Los Angeles, CA 90095, USA.
Jiulong LiCenter of Environmental Implications of Nanotechnology (UC CEIN), University of California, Los Angeles, CA 90095, USA.
Tian XiaCenter of Environmental Implications of Nanotechnology (UC CEIN), University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-0123-1305
Andre E NelCenter of Environmental Implications of Nanotechnology (UC CEIN), University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-5232-4686
California NanoSystems Institute · US

Funding

Toxicological Profiling of Engineered Nanomaterials (ENMs) in the MPS (RES)U01ES027237 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS, XIA, TIAN · 2016 to 2020
$2.2M
NIEHS NIH HHS U01 ES027237
6 · The paper itself

Abstract

To address the urgent need for safe food allergen immunotherapy, we have developed a liver-targeting nanoparticle platform, capable of intervening in allergic inflammation, mast cell release and anaphylaxis through the generation of regulatory T-cells (Treg). In this communication, we demonstrate the use of a poly (lactide-co-glycolide acid) (PLGA) nanoparticle platform for intervening in peanut anaphylaxis through the encapsulation and delivery of a dominant protein allergen, Ara h 2 and representative T-cell epitopes, to liver sinusoidal endothelial cells (LSECs). These cells have the capacity to act as natural tolerogenic antigen-presenting cells (APC), capable of Treg generation by T-cell epitope presentation by histocompatibility (MHC) type II complexes on the LSEC surface. This allowed us to address the hypothesis that the tolerogenic nanoparticles platform could be used as an effective, safe, and scalable intervention for suppressing anaphylaxis to crude peanut allergen extract. Following the analysis of purified Ara h 2 and representative MHC-II epitopes Treg generation

Indexed as

anaphylaxisAra h2 T-cell epitopeimmunotherapyliver-targetingPeanut allergytolerogenic nanoparticle

Identifiers

PMID36969911
PMCPMC10038170
OpenAlexW4205335057

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.